Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

BACKGROUND: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. METHODS: We studied 14 298 patients with atheroscl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation
Hlavní autoři: Marston, Nicholas A., Kamanu, Frederick K., Nordio, Francesco, Gurmu, Yared, Roselli, Carolina, Sever, Peter S., Pedersen, Terje R., Keech, Anthony C., Wang, Huei, Pineda, Armando Lira, Giugliano, Robert P., Lubitz, Steven A., Ellinor, Patrick T., Sabatine, Marc S., Ruff, Christian T.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058781/
https://ncbi.nlm.nih.gov/pubmed/31707849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.043805
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky